Corpus Intelligence IC Memo — TYLER HEALTHCARE CENTER 2026-04-26 15:02 UTC
IC Memo — TYLER HEALTHCARE CENTER
Investment Committee Memorandum | MN | 21 beds | Grade C | EBITDA uplift $948K
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

TYLER HEALTHCARE CENTER

CCN 241348 | LINCOLN, MN | 21 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

TYLER HEALTHCARE CENTER is a 21-bed rural/critical access in LINCOLN, MN with $12.8M in net patient revenue and a 0.7% operating margin. The hospital serves a payer mix of 48.5% Medicare, 0.5% Medicaid, and 51.0% commercial.

Thesis: Turnaround. Our ML models identify $948K in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 0.7% to 8.1% (+738bps).

Net Revenue HCRIS$12.8M
Current EBITDA COMPUTED$93K
Operating Margin COMPUTED0.7%
Occupancy HCRIS7.5%
Revenue / Bed COMPUTED$611K
Net-to-Gross HCRIS64.0%
Distress Probability ML62.1%

2. Market Context & Competitive Position

141
MN Hospitals
-3.6%
State Median Margin
93
Comparable Hospitals

MN has 141 Medicare-certified hospitals with a median operating margin of -3.6%. The target's margin of 0.7% places it above the state median. Among 93 size-comparable peers (10-42 beds), the median margin is -2.6%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (10-42), prioritizing same-state peers. 93 hospitals in the comp set.

HospitalStateBedsRevenueMargin
TYLER HEALTHCARE CENTER (Target)MN21$12.8M0.7%
CUYUNA REGIONAL MEDICAL CENTERMN25$180.8M-4.0%
ST. MARYS REGIONAL HEALTH CENTMN36$167.8M3.1%
MAYO CLINIC HEALTH SYSTEM - REMN27$149.3M1.8%
NEW ULM MEDICAL CENTERMN24$128.6M4.2%
LAKEWOOD HEALTH SYSTEMMN25$124.7M0.2%
NORTHFIELD CITY HOSPITALMN37$121.8M-8.4%
GRAND ITASCA CLINIC AND HOSPITMN34$117.7M5.3%
AVERA MARSHALL REGIONAL MEDICAMN25$115.2M-17.0%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $948K (738bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$270K+210bp18mo
Cost to Collect4.5%2.5%$257K+200bp12mo
Denial Rate Reduction12.0%6.5%$255K+199bp12mo
A/R Days Reduction5200.0%3800.0%$156K+122bp9mo
Clean Claim Rate88.0%96.0%$10K+7bp6mo

5. EBITDA Bridge

Net Collection Rate
$270K
Cost to Collect
$257K
Denial Rate Reduction
$255K
A/R Days Reduction
$156K
Clean Claim Rate
$10K
Total EBITDA Uplift$948K
Current EBITDA$93K
+ RCM Uplift+$948K
Pro Forma EBITDA$1.0M
Current Margin0.7%
Pro Forma Margin8.1%
WC Released (1x)$492K

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$144K$10.1M70.25x134.1%
Base (11x exit)10.0x11.0x$144K$11.1M77.60x138.8%
Bull Case9.0x11.0x$129K$14.3M110.77x156.4%
Bull (12x exit)9.0x12.0x$129K$15.7M121.14x161.0%
Bear Case11.0x10.0x$158K$5.3M33.59x101.9%
Bear (11x exit)11.0x11.0x$158K$5.9M37.27x106.2%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumLow occupancyAt 7.5%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case
HighElevated distress probabilityModel estimates 62.1% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 93 hospitals with 10-42 beds
  • Same-state prioritization (n=94)
  • Comp margins: P25=-12.1% / P50=-2.6% / P75=3.4%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.